Dear Healthcare Professional, Biogen ldec and Elan are writing to inform you of new safety information regarding TYSABRI" (natalizumab). The full Prescribing Information has been revised to add to the   more »

A letter posted to the Food and Drug Administration's Web site says that patients taking Tysabri, which is manufactured at a facility in Research Triangle Park, have developed signs of liver injury as soon as six days after taking their first dose.   more »

Q. Where can I call to get more information about Tysabri? The Tysabri Care Program is a registry that supports the safe and effective use of Tysabri. Its goals are to: · To inform people about the risks and benefits of Tysabri prior to treatment   more »

Q. Will my insurance cover the cost of Tysabri? A. According to Biogen Idec Canada, most private insurers are now reimbursing the cost of Tysabri. Generally insurance companies require prior authorization before they will   more »

Q. What is Tysabri (pronounced Tie-SAB-bree) and how does it work? A. Tysabri (whose scientific name is natalizumab, pronounced: nat-tal-IZ-zue-mab) is a laboratory-produced monoclonal antibody. It was formerly called Antegren. It had been approved for   more »

Although most hypersensitive reactions to natalizumab (Tysabri) occur within hours of the first dose, such responses may be delayed, according to   more »

NICE Recommends TYSABRI® for Use in Highly Active Relapsing Remitting Multiple Sclerosis

 

Final Guidance Issued on First MS Treatment Recommended by NICE

 

MAIDENHEAD, ...   more »

New Data on Natalizumab Demonstrate Significant Improvement in Cognitive Function in Patients With Multiple Sclerosis

 

 ZUG, SWITZERLAND and DUBLIN, IRELAND –

 

September ...   more »